Gilead Sciences, Inc. (NASDAQ:GILD) Shares Purchased by Harvest Fund Management Co. Ltd

Harvest Fund Management Co. Ltd increased its position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 41.0% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 80,889 shares of the biopharmaceutical company's stock after buying an additional 23,512 shares during the period. Harvest Fund Management Co. Ltd's holdings in Gilead Sciences were worth $7,375,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in GILD. Swedbank AB increased its holdings in shares of Gilead Sciences by 10.2% in the 3rd quarter. Swedbank AB now owns 2,047,609 shares of the biopharmaceutical company's stock worth $171,672,000 after buying an additional 189,622 shares during the last quarter. Natixis Advisors LLC raised its position in Gilead Sciences by 18.1% during the third quarter. Natixis Advisors LLC now owns 169,363 shares of the biopharmaceutical company's stock valued at $14,199,000 after purchasing an additional 25,912 shares during the period. Quest Partners LLC lifted its stake in shares of Gilead Sciences by 163.4% in the 3rd quarter. Quest Partners LLC now owns 8,400 shares of the biopharmaceutical company's stock valued at $704,000 after purchasing an additional 5,211 shares during the last quarter. OneAscent Wealth Management LLC purchased a new position in shares of Gilead Sciences in the 3rd quarter worth approximately $203,000. Finally, Aviance Capital Partners LLC boosted its holdings in shares of Gilead Sciences by 6.5% in the 3rd quarter. Aviance Capital Partners LLC now owns 18,616 shares of the biopharmaceutical company's stock worth $1,561,000 after purchasing an additional 1,138 shares during the period. 83.67% of the stock is owned by institutional investors.

Remove Ads

Insider Activity at Gilead Sciences

In related news, CFO Andrew D. Dickinson sold 17,929 shares of the business's stock in a transaction on Monday, March 10th. The stock was sold at an average price of $118.17, for a total transaction of $2,118,669.93. Following the transaction, the chief financial officer now directly owns 169,061 shares in the company, valued at $19,977,938.37. The trade was a 9.59 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Insiders sold 302,785 shares of company stock valued at $30,503,250 over the last 90 days. Insiders own 0.29% of the company's stock.

Gilead Sciences Stock Up 1.1 %

NASDAQ GILD traded up $1.21 during midday trading on Friday, hitting $107.08. 26,496,292 shares of the company traded hands, compared to its average volume of 6,793,320. The company has a market cap of $133.35 billion, a PE ratio of 289.41, a price-to-earnings-growth ratio of 0.71 and a beta of 0.21. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.50 and a quick ratio of 1.20. Gilead Sciences, Inc. has a 52 week low of $62.07 and a 52 week high of $119.96. The company's 50-day simple moving average is $103.68 and its 200-day simple moving average is $93.85.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share for the quarter, beating analysts' consensus estimates of $1.67 by $0.23. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. As a group, equities research analysts forecast that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 28th. Investors of record on Friday, March 14th will be paid a dividend of $0.79 per share. This represents a $3.16 annualized dividend and a dividend yield of 2.95%. The ex-dividend date of this dividend is Friday, March 14th. This is a positive change from Gilead Sciences's previous quarterly dividend of $0.77. Gilead Sciences's payout ratio is 854.05%.

Analysts Set New Price Targets

A number of analysts recently issued reports on the company. Piper Sandler raised their price target on Gilead Sciences from $105.00 to $110.00 and gave the stock an "overweight" rating in a research report on Wednesday, February 12th. Cantor Fitzgerald restated a "neutral" rating and issued a $80.00 target price on shares of Gilead Sciences in a report on Wednesday, December 11th. Needham & Company LLC reiterated a "hold" rating on shares of Gilead Sciences in a report on Wednesday, February 12th. JPMorgan Chase & Co. increased their price objective on shares of Gilead Sciences from $105.00 to $115.00 and gave the stock an "overweight" rating in a research report on Wednesday, January 29th. Finally, Morgan Stanley boosted their target price on Gilead Sciences from $123.00 to $130.00 and gave the company an "overweight" rating in a research report on Tuesday, March 11th. Eleven analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and four have given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $104.52.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.